Chinese Journal of Cancer Research

, Volume 14, Issue 1, pp 50–53 | Cite as

The preliminary results of treatment ofadvanced and recurrent malignant lymphoma by beac regimen supported with autologous hematopoietic stem cells transplantation

  • Huang Hui-qiang 
  • Jiang Wen-qi 
  • He You-jian 
  • Sun Xiao-fei 
  • Liu Dong-geng 
  • Xu Rui-hua 
  • Zhang Li 
  • Zhou Zhong-mei 
  • Lin Tong-yu 
  • Li Yu-hong 
  • Guan Zhong-zhen 
Articles
  • 10 Downloads

Abstract

Objective: High dose chemotherapy supported by autologous hematopoietic stem cells transplantation (AHSCT) has developed dramaticly in recent years and become the most effective approach to improve radical treatment for the chemo-sensitive lymphoma. The purposes of this study was to evaluate the efficacy and tolerance of preparative regimen BEAC and hematopoietic reconstitution after high dose chemotherapy in Chinese patients with advanced and recurrent lymphoma. Methods: After confirmed complete or partial remission from conventional chemotherapy, 24 patients with advanced or recurrent lymphoma including 1 recurrent HD and 23 NHL, 16 male and 8 female with median age of 29 (13–50) years, were enrolled into this study and treated by BEAC regimen (CTX 3600–4000 mg/m2, VP-16 1200 mg/m2. BCNU 300 mg/m2 and Ara-C 1500–2000 mg/m2). 3 patients were supported by ABMT and 21 by APBSCT. Mobilization regimen for APBSCT was CTX 3500 mg/m2 + G-CSF 3.5–5 µg/kg + Dexamethasone 10 mg. Autologous hematopoietic stem cells was re-infused 24–48 h after completion of high dose chemotherapy. Results: MNC 1.3 (1.0–1.7)×108/kg and MNC 1.8 (1.0–4.4)×108, CFU-GM 5.1 (1.9–9.6)×105/kg plus CD34 + cells 2.9 (1.9–8.7)×106/kg were re-infused in the ABMT group and APBSCT group respectively. All patients obtained prompt and sustained hematopoietic reconstitution. ANC≥0.5×109/L and Pt≥2.0×109/L were at day 9 (6–17) and day 10 (0–31) respectively. 16 patients were alive with median 21 (2–69) months follow-up till end of May, 2001. 1, 2 and 3 years survival rate were 60.5%, 50.1% and 50.1%, respectively. Non-hematologic toxicity was mild and tolerable. Conclusions: High dose chemotherapy supported by AHSCT in the treatment of previously-untreated poor-prognostic and recurrent lymphoma was a safe and effective modality. Further investigation was warranted.

Key words

Lymphoma Autologous hematopoietic Stem cells Transplantation High dose chemotherapy 

CLC number

R730.53 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Peterson BA. The role of transplantation in non-Hodgkin’s lymphoma [J]. J Clin Oncol 1994; 12:2524.PubMedGoogle Scholar
  2. [2]
    Vose JM. Treatment for non-Hodgkin’s lymphoma in relapse [J]. N Engl J Med 1995; 333:1565.PubMedCrossRefGoogle Scholar
  3. [3]
    Nademanee A, Molina A, O’Donnell MR, et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate-and high-grade lymphoma: International index high and high-intermediate risk group [J]. Blood 1997; 90:3844.PubMedGoogle Scholar
  4. [4]
    Martelli M, Vignetti M, Zinzani PL, et al. High dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplantin, and cytarabine in aggressive non- Hodgkin’s lymphoma with partial response to front line chemotherapy: A prospective randomized Italian multicenter study [J]. J Clin Oncol 1996; 14:534.PubMedGoogle Scholar
  5. [5]
    Pettengell R, Radford JA, Morgenstern GR, et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell tansplantation in poor-prognosis non-Hodgkin’s lymphoma [J]. J Clin Oncol 1996; 14:586.PubMedGoogle Scholar
  6. [6]
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma [J]. N Engl J Med 1995; 333:1540.PubMedCrossRefGoogle Scholar
  7. [7]
    Fanin R, Silvestri F, Geromin A, et al. Sequential intensive treatment with the F-MACHOP regimen (+/radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma in adults [J]. Leuk Lymphoma 1997; 24:369.PubMedGoogle Scholar
  8. [8]
    Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: Results of a BNLI randomized trial [J]. Lancet 1993; 341:1051.PubMedCrossRefGoogle Scholar
  9. [9]
    A predictive model for aggressive non- Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project [J]. N Engl J Med 1993; 329:987.Google Scholar
  10. [10]
    Brian JB, Matt K, Steven A, et al. Autologous hematopoietic cell transplantation for non-Hodgkin’s Lymphoma: 100 month follow-up [J]. Proc Am Soc Clin Oncol 2001; 20(part 1):9a.Google Scholar
  11. [11]
    Kleiner S, Kirsch A, Schwaner I, et al. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymhpomas: a phase I/II study [J]. Bone Marrow Transplantation 1997; 20:953.PubMedCrossRefGoogle Scholar
  12. [12]
    Moskowitz CH, Nimer SD, Glassman JR, et al. The international prognostic index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma [J]. Bone Marrow Transplant 1999; 23:561.PubMedCrossRefGoogle Scholar
  13. [13]
    Philip T, Guglielmi C, Chauvin F, et al. Autologous bone marrow transplantation (ABMT) versus conventional chemotherapy (DHAP) in relapsed non-Hodgins lymphoma: final analysis of the Parma randomized study (216 patient) [J]. Proc Am Soc Clin Oncol 1995; 14:340.Google Scholar
  14. [14]
    Corinne Haioun, Eric lepage, Christian Gissilbrecht, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87-2 [J]. J Clin Oncol 1997; 15:1131.PubMedGoogle Scholar
  15. [15]
    Gianni AM, Bregni M, Siena S, et al. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma [J]. N Engl J Med 1997; 336:1290.PubMedCrossRefGoogle Scholar
  16. [16]
    Prince HM, Imrie K, Crump N, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin’s lymphoma: Identification of major prognostic groups [J]. Br J Haematol 1996; 92:880.PubMedCrossRefGoogle Scholar

Copyright information

© the Editorial Board of Chinese Journal of Cancer Research 2002

Authors and Affiliations

  • Huang Hui-qiang 
    • 1
  • Jiang Wen-qi 
    • 1
  • He You-jian 
    • 1
  • Sun Xiao-fei 
    • 1
  • Liu Dong-geng 
    • 1
  • Xu Rui-hua 
    • 1
  • Zhang Li 
    • 1
  • Zhou Zhong-mei 
    • 1
  • Lin Tong-yu 
    • 1
  • Li Yu-hong 
    • 1
  • Guan Zhong-zhen 
    • 1
  1. 1.Department of Medical Oncology, Cancer CenterSun Yat -sen University of Medical SciencesGuangzhou

Personalised recommendations